Geode Capital Management LLC Acquires 27,812 Shares of NextCure, Inc. (NASDAQ:NXTC)

Geode Capital Management LLC raised its holdings in NextCure, Inc. (NASDAQ:NXTC) by 14.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 223,741 shares of the company’s stock after purchasing an additional 27,812 shares during the quarter. Geode Capital Management LLC owned approximately 0.80% of NextCure worth $307,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Logos Global Management LP raised its position in NextCure by 29.9% in the 2nd quarter. Logos Global Management LP now owns 2,500,000 shares of the company’s stock valued at $3,975,000 after purchasing an additional 575,000 shares during the last quarter. Armistice Capital LLC acquired a new stake in shares of NextCure in the 2nd quarter valued at $57,000. Affinity Asset Advisors LLC increased its stake in shares of NextCure by 24.2% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,687,955 shares of the company’s stock valued at $2,684,000 after buying an additional 328,918 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of NextCure by 15.4% in the 2nd quarter. Renaissance Technologies LLC now owns 462,144 shares of the company’s stock valued at $735,000 after buying an additional 61,744 shares during the period. Institutional investors own 42.65% of the company’s stock.

NextCure Stock Performance

NASDAQ NXTC opened at $0.78 on Tuesday. The stock has a fifty day moving average of $1.08 and a 200-day moving average of $1.34. The stock has a market capitalization of $21.79 million, a P/E ratio of -0.37 and a beta of 0.67. NextCure, Inc. has a 52 week low of $0.76 and a 52 week high of $2.57.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their target price on NextCure from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Monday, November 11th.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.